John A. Moran Eye Center retinal specialist and researcher Paul S. Bernstein, MD, PhD, diagnosed John Ehrman with a rare eye disease known as Macular Telangiectasia Type 2 (MacTel) in 2014. The ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of ...

The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia (MacTel) type 2, Neurotech Pharmaceuticals announced on Thursday. A rare, ...

Please provide your email address to receive an email when new articles are posted on . Macular telangiectasia type 2 (MacTel) is a rare, retinal, neurodegenerative, bilateral disease that causes a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Innovative drug classes and advanced delivery systems ...

The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, ...

Add Yahoo as a preferred source to see more of our stories on Google. Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a rare ...

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved Encelto ...

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study ...

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, announces that the U.S. Food and Drug Administration (FDA), ...